1. Signaling Pathways
  2. Protein Tyrosine Kinase/RTK
  3. FGFR
  4. FGFR Inhibitors

FGFR Inhibitors

FGFR

FGFR1

FGFR2

FGFR3

FGFR4

FGF21

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.

FGFR Inhibitors, Agonists & Activators
Product Name FGFR FGFR1 FGFR2 FGFR3 FGFR4 FGF21 Purity
Lenvatinib  
FGFR1, IC50: 46 nM
        99.84%
Nintedanib  
FGFR1, IC50: 69 nM
FGFR2, IC50: 37 nM
FGFR3, IC50: 108 nM
    99.94%
Ponatinib  
FGFR1, IC50: 2.2 nM
        99.43%
Erdafitinib  
FGFR1, IC50: 1.2 nM
FGFR2, IC50: 2.5 nM
FGFR3, IC50: 3.0 nM
FGFR4, IC50: 5.7 nM
  99.66%
H3B-6527  
FGFR1, IC50: 320 nM
FGFR2, IC50: 1290 nM
FGFR3, IC50: 1060 nM
FGFR4, IC50: <1.2 nM
  ≥98.0%
Infigratinib  
FGFR1, IC50: 0.9 nM
FGFR2, IC50: 1.4 nM
FGFR3, IC50: 1 nM
FGFR4, IC50: 60 nM
  99.72%
Pemigatinib  
FGFR1, IC50: 0.4 nM
FGFR2, IC50: 0.5 nM
FGFR3, IC50: 1.2 nM
FGFR4, IC50: 30 nM
  99.73%
Pazopanib  
FGFR1, IC50: 140 nM
        99.91%
Futibatinib  
FGFR1, IC50: 3.9 nM
FGFR2, IC50: 1.3 nM
wild-type FGFR2, IC50: 0.3 nM
FGFR2 V5651, IC50: 1-3 nM
FGFR2 N550H, IC50: 3.6 nM
FGFR2 E566G, IC50: 2.4 nM
FGFR3, IC50: 1.6 nM
FGFR4, IC50: 8.3 nM
  99.65%
Fexagratinib  
FGFR1, IC50: 0.2 nM
FGFR2, IC50: 2.5 nM
FGFR3, IC50: 1.8 nM
FGFR4, IC50: 165 nM
  99.85%
Formononetin    
FGFR2, IC50: 4.31 μM
      99.92%
PD173074  
FGFR1, IC50: 25 nM
        99.70%
SU 5402  
FGFR1, IC50: 30 nM
        99.38%
Nintedanib esylate  
FGFR1, IC50: 69 nM
FGFR2, IC50: 37 nM
FGFR3, IC50: 108 nM
    99.95%
Lenvatinib mesylate  
FGFR1, IC50: 46 nM
        99.86%
Dovitinib  
FGFR1, IC50: 8 nM
 
FGFR3, IC50: 9 nM
    99.94%
KW-2449  
FGFR1, IC50: 36 nM
        99.69%
Ferulic acid  
FGFR1, IC50: 3.78 μM
FGFR2, IC50: 12.5 μM
      99.87%
PD-166866  
FGFR1, IC50: 52.4 nM
        99.89%
Fisogatinib        
FGFR4, IC50: 5 nM
  99.87%
Gandotinib    
FGFR2, IC50: 32 nM
FGFR3, IC50: 106 nM
    99.82%
BLU9931  
FGFR1, IC50: 591 nM
FGFR2, IC50: 493 nM
FGFR3, IC50: 150 nM
FGFR4, IC50: 3 nM
  99.95%
Roblitinib  
FGFR1, IC50: >10 μM
FGFR2, IC50: >10 μM
FGFR3, IC50: >10 μM
FGFR4, IC50: 1.9 nM
rat FGFR4, IC50: >10 μM
  99.74%
Pazopanib Hydrochloride  
FGFR1, IC50: 140 nM
        99.88%
Sulfatinib  
FGFR1
        98.65%
LY2874455  
FGFR1, IC50: 2.8 nM
FGFR2, IC50: 2.6 nM
FGFR3, IC50: 6.4 nM
FGFR4, IC50: 6 nM
  98.03%
Rogaratinib  
FGFR1
FGFR2
FGFR3
FGFR4
  99.86%
Lirafugratinib    
FGFR2, IC50: 3 nM
      99.60%
Ponatinib hydrochloride  
FGFR1, IC50: 2.2 nM
        99.55%
Efruxifermin          
FGF21
98.32%
Surfen dihydrochloride    
FGFR2, IC50: 5 μM
      ≥99.0%
Orantinib  
FGFR1, Ki: 1.2 μM
        99.21%
Lucitanib  
FGFR1, IC50: 17.5 nM
FGFR2, IC50: 82.5 nM
      98.94%
Alofanib    
FGFR2
      99.90%
PF 477736      
FGFR3, IC50: 23 nM
    99.21%
ENMD-2076  
FGFR1, IC50: 92.7 nM
FGFR2, IC50: 70.8 nM
      99.12%
CP-547632
FGFR, IC50: 9 nM
          99.16%
ODM-203  
FGFR1, IC50: 11 nM
FGFR2, IC50: 16 nM
FGFR3, IC50: 6 nM
FGFR4, IC50: 35 nM
  99.91%
Zoligratinib  
FGFR1, IC50: 9.3 nM
FGFR2, IC50: 7.6 nM
FGFR3, IC50: 22 nM
FGFR4, IC50: 290 nM
  99.76%
ASP5878  
FGFR1, IC50: 0.47 nM
FGFR2, IC50: 0.6 nM
FGFR3, IC50: 0.74 nM
FGFR4, IC50: 3.5 nM
  99.86%
SSR128129E  
FGFR1, IC50: 1.9 μM
        99.85%
Infigratinib phosphate  
FGFR1, IC50: 0.9 nM
FGFR2, IC50: 1.4 nM
FGFR3, IC50: 1 nM
FGFR4, IC50: 60 nM
  99.74%
PRN1371  
FGFR1, IC50: 0.6 nM
FGFR2, IC50: 1.3 nM
FGFR3, IC50: 4.1 nM
FGFR4, IC50: 19.3 nM
  99.43%
CP-547632 hydrochloride
FGFR, IC50: 9 nM
          99.88%
Derazantinib  
FGFR1, IC50: 4.5 nM
FGFR2, IC50: 1.8 nM
FGFR3, IC50: 4.5 nM
    99.28%
Vofatamab      
FGFR3
   
FIIN-2  
FGFR1, IC50: 3.1 nM
FGFR2, IC50: 4.3 nM
FGFR3, IC50: 27 nM
FGFR4, IC50: 45 nM
  99.63%
Aprutumab    
FGFR2-IIIb
FGFR2-IIIc
     
Dovitinib lactate  
FGFR1, IC50: 8 nM
 
FGFR3, IC50: 9 nM
    99.62%
FGFR2-IN-2  
FGFR1, IC50: 389 nM
FGFR2, IC50: 29 nM
FGFR3, IC50: 758 nM
    98.09%
TG 100572 Hydrochloride  
FGFR1, IC50: 2 nM
FGFR2, IC50: 16 nM
      98.96%
Lirafugratinib hydrochloride    
FGFR2, IC50: 3 nM
      98.73%
FGFR3-IN-5  
FGFR1, IC50: 289 nM
FGFR2, IC50: 44 nM
FGFR3, IC50: 3 nM
    99.28%
Tyrosine kinase-IN-1  
FGFR1, IC50: 2 nM
        99.34%
ENMD-2076 Tartrate  
FGFR1, IC50: 92.7 nM
FGFR2, IC50: 70.8 nM
      99.42%
FGFR1/DDR2 inhibitor 1  
FGFR1, IC50: 31.1 nM
        98.26%
E7090  
FGFR1, IC50: 0.71 nM
FGFR2, IC50: 0.50 nM
FGFR3, IC50: 1.2 nM
FGFR4, IC50: 120 nM
  99.64%
CPL304110  
FGFR1, IC50: 0.75 nM
FGFR2, IC50: 0.5 nM
FGFR3, IC50: 3.05 nM
    99.68%
TG 100801  
FGFR1, IC50: 2 nM
FGFR2, IC50: 16 nM
      98.60%
Gunagratinib
FGFR
          99.36%
R1530  
FGFR1, IC50: 28 nM
        99.06%
FIIN-1  
FGFR1, Kd: 2.8 nM
FGFR1, IC50: 9.2 nM
FGFR2, Kd: 6.9 nM
FGFR2, IC50: 6.2 nM
FGFR3, Kd: 5.4 nM
FGFR3, IC50: 11.9 nM
FGFR4, Kd: 120 nM
FGFR4, IC50: 189 nM
  99.11%
SU4984  
FGFR1, IC50: 10-20 μM
        99.14%
EOC317  
FGFR1, IC50: 6 nM
        98.05%
S49076  
FGFR1, IC50: 18 nM
FGFR1V561M, IC50: 23 nM
FGFR2, IC50: 17 nM
FGFR2N549H, IC50: 19 nM
FGFR3, IC50: 15 nM
    99.71%
FGFR1 inhibitor-10  
FGFR1
        98.92%
PD-089828  
FGFR1, IC50: 0.15 μM
FGFR1, Ki: 0.14 μM
        98.07%
FIIN-3  
FGFR1, IC50: 13.1 nM
FGFR2, IC50: 21 nM
FGFR3, IC50: 31.4 nM
FGFR4, IC50: 35.3 nM
  99.66%
FGFR4-IN-5    
FGFR2, IC50: 505 nM
 
FGFR4, IC50: 6.5 nM
  98.03%
VSPPLTLGQLLS      
FGFR3
K650M-FGFR3
K644E FGFR3
    98.08%
Fazpilodemab  
FGFR1c
        99.00%
Recifercept      
FGFR3
   
JK-P3  
FGFR1, IC50: 27 μM
 
FGFR3, IC50: 5.18 μM
    99.72%
(Z)-Orantinib  
FGFR1, IC50: 1.2 μM
        99.02%
LC-MB12    
FGFR2, DC50: 11.8 nM
      99.23%
CP-547632 TFA
FGFR, IC50: 9 nM
          99.42%
TG 100572  
FGFR1, IC50: 2 nM
FGFR2, IC50: 16 nM
     
Dovitinib lactate hydrate  
FGFR1, IC50: 8 nM
 
FGFR3, IC50: 9 nM
   
E7090 succinate  
FGFR1, IC50: 0.71 nM
FGFR2, IC50: 0.50 nM
FGFR3, IC50: 1.2 nM
FGFR4, IC50: 120 nM
  99.17%
FGFR4-IN-11        
FGFR4, IC50: 2.1 nM
 
FGFR4-IN-4        
FGFR4
 
FGFR1 inhibitor-2  
FGFR1
       
ARQ 069  
unphosphorylated FGFR1, IC50: 0.84 μM
FGFR1 autophosphorylation, IC50: 2.8 μM
unphosphorylated FGFR2, IC50: 1.23 μM
FGFR2 autophosphorylation, IC50: 1.9 μM
     
FGFR3-IN-6      
FGFR3
   
FGFR-IN-2  
FGFR1, IC50: 7.3 nM
FGFR2, IC50: 4.3 nM
FGFR3, IC50: 7.6 nM
FGFR4, IC50: 11 nM
 
FGFR3-IN-4      
FGFR3, IC50: < 50 nM
   
FGFR-IN-9  
FGFR1, IC50: 64.3 nM
FGFR2, IC50: 46.7 nM
FGFR3, IC50: 29.6 nM
FGFR4WT, IC50: 17.1 nM
FGFR4V550L, IC50: 30.7 nM
 
FGFR-IN-8  
FGFR1, IC50: <0.5 nM
V561M-FGFR1, IC50: 262.5 nM
V564F-FGFR2, IC50: 189.1 nM
N549H-FGFR2, IC50: <0.5 nM
V555M-FGFR3, IC50: 22.6 nM
FGFR3, IC50: <0.5 nM
K650E-FGFR3, IC50: <0.5 nM
K650M-FGFR3, IC50: 4.8 nM
FGFR4, IC50: 7.30 nM
 
FGFR3-IN-2      
FGFR3, IC50: 4.1 nM
   
FGFR-IN-10    
FGFR2, IC50: 104.1 nM
V564F-FGFR2, IC50: 43.6 nM
     
FGFR4-IN-10        
FGFR4, IC50: 70.7 nM
 
FGFR3-IN-7      
FGFR3
   
CXF-009        
FGFR4, IC50: 48 nM
 
FGFR2/3-IN-1  
FGFR1, IC50: 21 nM
FGFR2, IC50: 1 nM
FGFR3, IC50: 0.5 nM
FGFR3 V555L, IC50: 2.7 nM
FGFR3 V555M, IC50: 6.1 nM
FGFR4, IC50: 145 nM
 
FGFR2-IN-1    
FGFR2, IC50: 140 nM
      99.78%
Picrasidine Q    
FGFR2
     
FGFR-IN-11  
FGFR1, IC50: 9.9 nM
FGFR2, IC50: 3.1 nM
FGFR3, IC50: 16 nM
FGFR4, IC50: 1.8 nM
 
3-Methylthienyl-carbonyl-JNJ-7706621    
FGFR2, IC50: 0.22 μM
     
Multi-kinase-IN-2  
FGFR1, IC50: 23 ± 2.5 nM
       
FGFR4-IN-9        
FGFR4, IC50: 75.3 nM
 
Multi-kinase-IN-5  
FGFR1, IC50: 1.287 μM
       
HDAC-IN-50  
FGFR1, IC50: 0.18 nM
FGFR2, IC50: 1.2 nM
FGFR3, IC50: 0.46 nM
FGFR4, IC50: 1.4 nM
 
FGFR1 inhibitor-6  
FGFR1, IC50: 16.31 nM
       
VSPPLTLGQLLS TFA      
FGFR3
K650M-FGFR3
K644E FGFR3
   
FGFR3-IN-3  
FGFR1, IC50: 2.1 nM
FGFR2, IC50: 3.1 nM
FGFR3, IC50: 4.3 nM
FGFR4, IC50: 74 nM
 
FGFR3-IN-1  
FGFR1, IC50: 40 nM
FGFR2, IC50: 5.1 nM
FGFR3, IC50: 12 nM
   
CXF-007        
FGFR4, IC50: 7 nM
 
TG 100801 Hydrochloride  
FGFR1, IC50: 2 nM
FGFR2, IC50: 16 nM
     
SSR128129E free acid  
FGFR1, IC50: 1.9 μM